CMOs and private equity on buying spree for dose manufacturing pharmaceutical-technology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-technology.com Daily Mail and Mail on Sunday newspapers.
Published: Jul 06, 2021 By Vanessa Doctor, RN
Peter Macdiarmid/Getty Images
Global clinical research organization
PAREXEL International has agreed to be taken over from Pamplona Capital Management for $8.5 billion. Upon completion of the
merger, Parexel will be owned by EQT IX Fund and the private equity business within Goldman Sachs Asset Management.
Parexel is dually headquartered in Newton and Durham, North Carolina and specializes in developing new innovations in medicine to improve patient health. It engages in decentralized clinical trials, regulatory consultations, and leveraging insights from data. The definitive agreement is still subject to compliance conditions and other customary factors.
The merger with EQT, a global purpose-driven investment firm, adds to Parexel s pharmacological research capabilities. EQT has over € 67 billion (approx.. $79.2 billion) in assets under management spread out across 26 active funds. Its holdings have portfolios
Rising Meat and Dairy Consumption to Drive Animal Feed Probiotics Sales: Fact MR yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.